JW Therapeutics to raise $20 million in share placement at 3% discount

Cell immunotherapy biotechnology company JW (Cayman) Therapeutics Co. Ltd. (2126.HK) said on Sunday it plans to issue 61.19 million new shares to two institutional investors at a subscription price of HK$2.615 per share, representing a 2.97% discount to last Friday’s closing price. The sale will raise gross proceeds of HK$160 million and net proceeds of approximately HK$158.8 million ($20 million).
The new shares will represent approximately 12.8% of the company’s enlarged share capital. The company will use 40% of the proceeds to fund R&D of its in vivo CAR-T products, 30% will support R&D of its autologous CAR-T products, and 20% will go toward upgrading its technology platforms and manufacturing capabilities. The remainder will be used for working capital.
The company announced the same day that its core product, Carteyva (relmacabtagene autoleucel injection), has been included in China’s 2026 National Reimbursement Drug List (NRDL), covering its three approved lymphoma indications at an NRDL price of 288,600 yuan. From next year, eligible patients will qualify for reimbursement using the drug under basic medical insurance, helping ease their treatment costs.
The company’s shares opened higher on Monday and surged more than 14% in early trading before reversing course, falling 7.79% to HK$2.485 by the midday break and bringing their year-to-date loss to 1.8%.
By Lee Shih Ta
To subscribe to Bamboo Works weekly free newsletter, click here